ABSTRACT
The impact of SES implantation on the risk of subsequent clinically driven target vessel revascularization in specific subsets is shown in Figure 3.3. Sirolimus-eluting stent implantation was associated with a risk reduction that ranged from 28% to 79% across the subgroups evaluated. However, the benefit
myocardial infarction or target vessel revascularization in patients treated with bare stents before the introduction of SES (PreSES group) and in patients treated exclusively with SES implantation (SES Group). (From Lemos et al.30a)
Figure 3.2 One-year cumulative risk of clinically driven target vessel revascularization in patients treated with bare stents before the introduction of SES (PreSES group) and in patients treated exclusively with SES implantation (SES Group). (From Lemos et al.30a)
